EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study

Kyoko Miyamoto iD, Robert M Miller iD, Christine Voors-Pette, Jart A F Oosterhaven iD, Marieke van den Dobbelsteen, Katsuhiro Mihara iD, Marian Geldof, Yuji Sato, Naomi Matsuda, Shirou Kirita, Masaaki Sawa iD, Akinori Arimura iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.70060 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Kyoko Miyamoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: CarnaBio USA, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Healthy Volunteers, Protein Kinase Inhibitors, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Carna Biosciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton's tyrosine kinase (BTK) is a potential therapeutic target for allergic and autoimmune diseases. This first‐in‐human phase I study evaluated safety, pharmacokinetic, and pharmacodynamic profiles of sofnobrutinib (formerly AS‐0871), a highly selective, orally available, non‐covalent BTK inhibitor, in healthy adult subjects. Single ascending doses (SAD; 5–900 mg) and multiple ascending doses (MAD; 50–300 mg twice daily [b.i.d.] for 14 days [morning dose only on Day 14]) of sofnobrutinib were tested. In the entire study, all adverse events (AEs) were mild or moderate, and no apparent dose‐proportional trend in severity or frequency was observed. No serious treatment‐emergent AEs, cardiac arrythmias, or bleeding‐related AEs were reported. In the SAD part, sofnobrutinib exhibited approximately dose‐dependent systemic exposures up to 900 mg with rapid absorption (median time to maximum concentration of 2.50–4.00 h) and gradual decline (mean half‐lives of 3.7–9.0 h). In the MAD part, sofnobrutinib showed low accumulation after multiple dosing (mean accumulation ratios of ≤1.54) and reached a steady state on ≤Day 7. Single dosing of sofnobrutinib rapidly and dose‐dependently suppressed basophil and B‐cell activations in ex vivo whole blood assays. Multiple dosing of sofnobrutinib achieved 50.8%–79.4%, 67.6%–93.6%, and 90.1%–98.0% inhibition of basophil activation during the dosing interval of 50, 150, and 300 mg b.i.d., respectively. Based on pharmacokinetic‐pharmacodynamic analysis, half‐maximal inhibitory concentration (IC 50 ) of sofnobrutinib for basophil activation was 54.06 and 57.01 ng/mL in the SAD and MAD parts, respectively. Similarly, IC 50 for B‐cell activation was 187.21 ng/mL. These data support further investigation of sofnobrutinib in allergic and autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseHealthy VolunteersProtein Kinase InhibitorsDose-Response Relationship, DrugHumansAdultMaleFemaleMiddle AgedYoung AdultDrug Administration ScheduleHalf-LifeAdministration, OralPyrimidinesAdolescent

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, humanPyrimidines

Autor:innen und Institutionen

  • CarnaBio USA, Inc., South San Francisco, California, USA.
  • Artemida Pharma, Ltd., Hertfordshire, UK.
  • QPS Netherlands BV, Groningen, The Netherlands.
  • ICON plc, Groningen, The Netherlands.
  • Venn Life Sciences ED B.V., Breda, The Netherlands.
  • Carna Biosciences, Inc., Kobe, Japan.

ORCID-Profile: Kyoko Miyamoto, Robert M Miller, Jart A F Oosterhaven, Katsuhiro Mihara, Masaaki Sawa, Akinori Arimura

Förderung

  • Carna Biosciences, Inc.

Zitieren

APA

Miyamoto, K., Miller, R. M., Voors-Pette, C., Oosterhaven, J. A. F., van den Dobbelsteen, M., Mihara, K., Geldof, M., Sato, Y., Matsuda, N., Kirita, S., Sawa, M., & Arimura, A. (2024). Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study. Clinical and Translational Science. https://doi.org/10.1111/cts.70060

Vancouver

Miyamoto K, Miller RM, Voors-Pette C, Oosterhaven JAF, van den Dobbelsteen M, Mihara K, et al. Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study. Clinical and Translational Science. 2024. doi:10.1111/cts.70060

BibTeX
@article{Miyamoto2024,
  author = {Miyamoto, Kyoko and Miller, Robert M and Voors-Pette, Christine and Oosterhaven, Jart A F and van den Dobbelsteen, Marieke and Mihara, Katsuhiro and Geldof, Marian and Sato, Yuji and Matsuda, Naomi and Kirita, Shirou and Sawa, Masaaki and Arimura, Akinori},
  title = {Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.70060}
}
Kostenlos starten →